PDUFA VIII Keeps Every Review Clock and Hires Four Auditors

PDUFA VIII Keeps Every Review Clock and Hires Four Auditors

by
PDUFA VIII Keeps Every Review Clock and Hires Four Auditors
In Depth CI read Legal & Policy/ Regulatory/ Market Access

PDUFA VIII Keeps Every Review Clock and Hires Four Auditors

Athithi Verma · 20 August 2026 · 5 min read · Synopulse

Industry has renegotiated what it pays FDA without meaningfully changing what it gets. The review clocks in the draft PDUFA VIII commitment letter are the clocks industry already had. What is new is an apparatus for verifying that the money produces reviewers: an entire section on hiring and retention, a financial transparency programme, and four separate independent assessments of how the agency actually works.

Executive snapshot
  • The headline performance goals did not move. PDUFA VIII retains 90% of standard new molecular entity applications acted on within 10 months of the 60-day filing date and 90% of priority applications within 6 months, the same targets industry has been buying for years.
  • What industry bought instead is verification. The letter devotes a top-level section to transparency in FDA hiring and retention of review staff, adds a financial transparency and resource capacity programme, and commissions four distinct independent third-party assessments, of first-cycle review, of meeting management, of the CMC facility programme and of enterprise performance.
  • The window is short and the calendar is public. GDUFA and PDUFA draft letters were published on 11 and 14 August. Public meetings fall on 16 and 17 September, requests to speak close on 2 and 3 September, and written comments close on 16 and 17 October, ahead of the 30 September 2027 expiry.

A user fee agreement is a purchase contract. Industry supplies money, the agency supplies review capacity, and the commitment letter specifies the deliverable. When the deliverable stays constant across a renegotiation and the audit provisions expand this sharply, the parties are not arguing about speed. They are arguing about whether the capacity being paid for will exist. A reader can stop here with the full picture. The sections below are the detail.

The clocks industry is buying in 2028 are the clocks it bought in 2023

The draft PDUFA VIII commitment letter covers fiscal years 2028 through 2032 and applies its enhanced review programme to applications received from 1 October 2027. Its first substantive table sets out the review performance goals, and they are the familiar ones: 90% of standard new molecular entity NDAs and original BLAs acted on within ten months of the 60-day filing date, 90% of priority applications within six months, with the same six and ten month structure carried across efficacy supplements and the two resubmission classes.

Around that stability sit genuine refinements. Multi-divisional meetings are formalised for products developed across several review divisions. Sponsors gain a defined route to request written responses rather than meetings, and a twenty-day clarifying question window after minutes are issued. A CMC facility lifecycle programme adds pre-submission and post-inspection meetings intended to stop manufacturing findings from generating complete response letters. Rare disease work continues, with the Rare Disease Endpoint Advancement programme capped at four proposals in FY2028 and six in FY2029 before converting to a standing meeting type.

These are process improvements. None of them changes the headline promise, which is the thing a sponsor plans a launch around.

FIGURE 1 The promise held still. The apparatus for checking it did not.WHAT INDUSTRY IS BUYING · UNCHANGED 90% in 10 months Standard NME NDAs and original BLAs 90% in 6 months Priority NME NDAs and original BLAsWHAT INDUSTRY ADDED · FOUR INDEPENDENT ASSESSMENTS First-cycle review outcomes and communications Meeting management enhancements CMC facility lifecycle programme Enterprise performance of the PDUFA programme Complete response rates, clock extensions, labelling exchanges Written responses, face-to-face rationales, multi-divisional meetings Impact on facility-driven complete responses Regulatory programme operations and organisational performance 2030 TO 2032 2030 TO 2032 BY SEP 2030 BY MAR 2029

Review performance goals and independent assessment commitments as set out in the draft PDUFA VIII commitment letter for fiscal years 2028 to 2032. Dates shown are the earliest published deliverable for each assessment stream.

Draft commitment letter as published · Federal Register 14 August 2026 · Compiled 20 August 2026

An entire section on whether FDA can keep its reviewers

The structural tell is in the table of contents. Alongside the sections on review effectiveness and information technology, the draft letter carries a top-level section titled transparency in FDA hiring and retention of review staff for the human drug review program. A performance goals letter has become a document in which staffing attrition is a named heading.

Section II reinforces it, committing FDA to resource capacity planning, financial transparency and an enterprise performance assessment. Holland and Knight’s analysis of the two draft letters notes that the PDUFA text cites high attrition during PDUFA VII, and that the GDUFA letter provides for an annual technical meeting with generic industry stakeholders on finance oversight following reductions in force.

Read the four independent assessments in that light and they stop looking like process hygiene. Contracting outside parties to quantify complete response rates, clock extensions, meeting conversions and organisational performance is what a buyer does when it wants evidence rather than assurance. This is the same reauthorisation cycle as MDUFA VI, where FDA must send Congress its recommendations by 15 January 2027, and the same 30 September 2027 expiry applies to all four human medical product programmes.

Where this touches access

The fee schedule is being used as industrial policy, which is new

The commercially consequential material sits in the fee structures rather than the performance goals. Per the same analysis, the draft GDUFA letter proposes raising the foreign facility fee from $15,000 to $25,000 to offset foreign inspection costs, and offers a one-time ANDA fee waiver to a US-based sponsor using US-only facilities for both active ingredient and finished dosage form. The draft PDUFA letter offers a 50% user fee reduction where an application includes clinical data from at least one Phase 1 trial anchored in the United States and initiated after 1 October 2027.

User fee programmes have historically traded money for review speed. A discount conditioned on where a Phase 1 trial runs, and a penalty conditioned on where a facility sits, are trade instruments delivered through a regulatory financing mechanism. If enacted, they change the arithmetic on site selection for early clinical work and on generic manufacturing footprint, independently of any scientific or regulatory judgement.

For access the effect is indirect but real. Generic entry timing drives the largest single source of price reduction in most systems, and a fee structure that advantages domestic facilities changes who can file economically and how quickly. A sponsor weighing a first-in-human site in 2027 now has a regulatory cost input in that decision that did not previously exist.

Three things to watch. Whether the domestic incentives survive the public meetings on 16 and 17 September, since they are the provisions most likely to attract objection from non-US filers. Whether Congress preserves them, given that final language rests with the committees rather than with the agency. And the Biosimilar User Fee Act letter, which is the only one of the four human product programmes still unpublished, because biosimilars are where a manufacturing-footprint incentive would bite hardest.